Oncology News

BARCELONA, Spain — Nivolumab did not significantly extend OS compared with sorafenib as first-line therapy for patients with advanced hepatocellular carcinoma, according to results of the randomized phase 3 CheckMate 459 trial presented at European Society for Medical Oncology Congress.

Treatment with Cabometyx as second-line therapy for patients with advanced hepatocellular carcinoma who previously received Nexavar demonstrated superior progression-free survival and improved overall survival compared with Stivarga, according to a study presented at the International Liver Cancer Association 2019 meeting and a press release.

Nanobiotix announced positive results of the NBTXR3 activated by stereotactic body radiation, or SBRT, for the treatment of hepatocellular carcinoma and liver metastasis, according to a press release.

Results from a systematic review and meta-analysis revealed 13 risk factors for intrahepatic and extrahepatic cholangiocarcinoma, the most significant of which included biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C.

Replacing serum creatinine with estimated glomerular filtration rate in a patient’s MELD-Na score appeared to improve waitlist mortality prediction among patients with cirrhosis in need of a liver transplantation, according to study results published in Hepatology.

Frailty correlated with a twofold higher risk for waitlist mortality among both patients with and without obesity in need of liver transplantation, which increased to a threefold higher risk in those with class 2 or higher obesity, according to a study published in JAMA Surgery.

A set of three prediction models for patients who required liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis estimated postoperative surgical risks and long-term survival rates.

Tiziana Life Sciences provided additional positive data from the ongoing phase 2a clinical trial of milciclib for patients with unresectable or metastatic hepatocellular carcinoma and resistance or intolerance to Nexavar.

Nonalcoholic fatty liver disease correlated with an approximately 90% higher risk for liver and gastrointestinal cancers compared with patients without fatty liver disease, while the association between obesity without fatty liver disease and cancer was small.

The Laboratory for Advanced Medicine announced via a press release that the FDA granted breakthrough device designation to its liquid biopsy liver cancer detection test.